Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic enzyme increased13.03.01.0190.004586%Not Available
Tinea infection23.09.02.004; 11.03.08.0020.001764%Not Available
Autoantibody positive13.06.01.0080.001058%Not Available
Blood test abnormal13.18.01.0030.001058%Not Available
Cardiac disorder02.01.01.003--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.001058%Not Available
Inflammation08.01.05.0070.003528%Not Available
Limb discomfort15.03.04.0140.001764%Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.008467%
Pseudomonas infection11.02.12.0010.000706%Not Available
Atypical mycobacterial infection11.04.02.0020.000706%Not Available
Food intolerance14.02.01.0050.000706%Not Available
Renal impairment20.01.03.010--Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000706%Not Available
Hepatic enzyme abnormal13.03.01.020--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Exfoliative rash23.03.07.0060.000706%Not Available
Treatment failure08.06.01.0170.000644%Not Available
Liver injury09.01.07.022; 12.01.02.0030.003175%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.000276%Not Available
Cholestatic liver injury09.01.07.0160.002117%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.002822%
Acute kidney injury20.01.03.016--
Drug-induced liver injury12.03.01.044; 09.01.07.0230.010231%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.005292%Not Available
Candida infection11.03.03.0210.002470%
Aspergillus infection11.03.01.0040.000276%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000552%
Liver function test increased13.03.01.0440.001058%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages